[PDF][PDF] Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia

G Etienne, J Guilhot, D Rea… - Journal of Clinical …, 2017 - clf1.medpagetoday.com
G Etienne, J Guilhot, D Rea, F Rigal-Huguet, F Nicolini, A Charbonnier, A Guerci-Bresler…
Journal of Clinical Oncology, 2017clf1.medpagetoday.com
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term
Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne, Joëlle Guilhot, Delphine Rea, Françoise Rigal-Huguet, Franck Nicolini, Aude
Charbonnier, Agn`es Guerci-Bresler, Laurence Legros, Bruno Varet, Martine Gardembas,
Viviane Dubruille, Michel Tulliez, Marie-Pierre Noel, Jean-Christophe Ianotto, Bruno …
Purpose
Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up.
clf1.medpagetoday.com